Bioinvent International Ab

This early-phase trial tests a new drug called BI-1910, alone or with pembrolizumab, in people with advanced solid tumors (like lung or liver cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug s…

This study tests a new drug called BI-1607 combined with two existing immunotherapies (ipilimumab and pembrolizumab) for people with advanced melanoma that has spread or cannot be removed. The goal is to see if adding BI-1607 helps the immune system better destroy cancer cells. A…